Biotech IPOs Hit the Wall

While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public companies.

Unfortunately, after a solid first quarter, the biotech IPO market has slowed considerably into the second quarter. While some companies are still able to get out -- Corium (NASDAQ: CORI  ) , Cerulean Pharma (NASDAQ: CERU  ) , and Adamas Pharmaceuticals (NASDAQ: ADMS  ) to name a few -- they're pricing below their ranges and aren't taking off once they hit the public markets, like we saw previously.

In the video below, senior biotech specialist Brian Orelli and health care bureau chief Max Macaluso discuss what the slowdown means for Corium, Cerulean Pharma, and Adamas Pharmaceuticals, as well as the companies still in the IPO queue, including MannKind (NASDAQ: MNKD  )  competitor Dance Pharma, which filed for a $75 million IPO this month.

This 2014 pick could be your next ten-bagger
Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2933278, ~/Articles/ArticleHandler.aspx, 8/31/2015 7:51:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:59 PM
ADMS $20.06 Down -0.55 -2.67%
CERU $4.03 Up +0.25 +6.61%
Cerulean Pharma CAPS Rating: ****
CORI $10.01 Down -0.44 -4.21%
MNKD $3.79 Down -0.13 -3.32%
MannKind Corp CAPS Rating: **